Artiva Biotherapeutics, Inc.
ARTV
$2.88
$0.113.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -99.25% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -99.25% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -100.00% | -99.25% | -- | -- |
| SG&A Expenses | 48.08% | 37.84% | 23.67% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.53% | 24.46% | 5.26% | -- | -- |
| Operating Income | -156.22% | -172.84% | -119.37% | -- | -- |
| Income Before Tax | -131.51% | -176.98% | -128.19% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.00% | -176.21% | -127.62% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.00% | -176.21% | -127.62% | -- | -- |
| EBIT | -156.22% | -172.84% | -119.37% | -- | -- |
| EBITDA | -168.03% | -187.66% | -128.32% | -- | -- |
| EPS Basic | 91.79% | 24.12% | -13.43% | -- | -- |
| Normalized Basic EPS | 92.68% | 46.88% | 18.79% | -- | -- |
| EPS Diluted | 94.12% | 57.76% | 34.33% | -- | -- |
| Normalized Diluted EPS | 94.02% | 57.87% | 34.58% | -- | -- |
| Average Basic Shares Outstanding | 2,742.15% | 2,020.85% | 1,298.47% | -- | -- |
| Average Diluted Shares Outstanding | 879.02% | 629.03% | 379.16% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |